Henry Schein (HSIC) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
4 Aug, 2026Executive summary
Achieved strong Q2 2026 results with 6.7% year-over-year sales growth to $3.5 billion and internal local currency sales growth of 4.6%.
Non-GAAP diluted EPS rose 15.5% to $1.27; GAAP diluted EPS was $0.82, up 17.1% year-over-year.
Value creation initiatives and technology advancements, especially in AI and cloud-based solutions, are driving higher profitability and engagement.
Raised FY2026 guidance for non-GAAP diluted EPS to $5.29–$5.39 and sales growth to 4.5%–5.5%.
Focused on accelerating growth, simplifying operations, operational rigor, and deepening customer relationships.
Financial highlights
Q2 2026 global sales reached $3.5 billion, up 6.7% year-over-year; internal local currency sales growth was 4.6%.
Non-GAAP operating income grew 10.5% to $250 million; non-GAAP net income was $145 million; GAAP net income was $94 million.
Adjusted EBITDA for Q2 was $288 million, up 12.7% year-over-year.
Gross margin improved to 31.8% (non-GAAP 31.83%).
Q2 2026 GAAP operating margin was 4.94%; non-GAAP operating margin was 7.21%.
Outlook and guidance
FY2026 total sales growth expected at 4.5%–5.5%; non-GAAP diluted EPS guidance raised to $5.29–$5.39.
Adjusted EBITDA for 2026 projected to grow mid to high single digits from $1.1 billion base.
Q4 earnings growth expected to exceed Q3, driven by sales momentum and value creation benefits.
Guidance excludes restructuring, amortization, and other non-recurring items; assumes stable FX rates and no further remeasurement gains.
The restructuring plan is expected to continue through 2027, with further charges anticipated.
Latest events from Henry Schein
- Global leader in dental and medical products with $13.2B sales and strong growth momentum.HSIC
Corporate presentation4 Aug 2026 - Record Q3 2025 results, raised guidance, and $200M+ value creation initiatives announced.HSIC
Q3 20258 Jul 2026 - Q2 2024 sales up 1.1% to $3.14B; net income and EPS declined, and guidance was reduced.HSIC
Q2 20248 Jul 2026 - Q4 2024 non-GAAP EPS rose 80% on 5.8% sales growth; 2025 outlook targets steady gains.HSIC
Q4 20248 Jul 2026 - Strategic initiatives and value creation projects drive stable growth and operational efficiency.HSIC
Baird Global Healthcare Conference 20258 Jul 2026 - Transformation, innovation, and disciplined growth drive strong outlook and value creation.HSIC
Stifel Jaws & Paws Conference 202627 May 2026 - Leadership changes, all proposals passed, and majority voting adopted for future governance.HSIC
AGM 202621 May 2026 - Strong Q1 growth, margin expansion, and strategic focus position the company for 2026 targets.HSIC
Bank of America Global Healthcare Conference 202613 May 2026 - Board urges support for director nominees and opposes majority vote proposal at annual meeting.HSIC
Proxy filing12 May 2026